At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Pre-Market Trading 03-26 06:56:22 EDT
2.69
-0.10
-3.58%
| High2.84 | Low2.63 | Vol595.95K |
| Open2.82 | D1 Closing2.79 | Amplitude7.71% |
| Mkt Cap97.48M | Tradable Cap75.49M | Total Shares36.24M |
| T/O1.60M | T/O Rate2.12% | Tradable Shares28.06M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Biomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler
Dow Jones · 03-25 23:35
BRIEF-Biomea Fusion Says Mick Hitchcock Named Interim CEO Replacing Thomas Butler
Reuters · 03-25 23:01
Biomea Fusion Announces Leadership Transition
THOMSON REUTERS · 03-25 23:00
Biomea Fusion Inc - Mick Hitchcock to Succeed Thomas Butler as Interim CEO Effective Immediately
THOMSON REUTERS · 03-25 23:00
Press Release: Biomea Fusion Announces Leadership Transition
Dow Jones · 03-25 23:00
Biomea Fusion announces presentation of icovamenib preclinical, clinical data
TipRanks · 03-25 12:50
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
TIPRANKS · 03-25 10:57
Barclays Sticks to Its Hold Rating for Biomea Fusion (BMEA)
TIPRANKS · 03-25 07:15
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 03-24 18:58
Freightos And 2 Other Penny Stocks Worth Watching
Simply Wall St. · 03-24 17:05
Freightos And 2 Other Penny Stocks Worth Watching
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow Jones · 03-24 14:48
Biomea Fusion Inc - Icovamenib Shows Sustained Reduction in Hba1c and Beta-Cell Function
THOMSON REUTERS · 03-24 12:30
Biomea Fusion Inc - Icovamenib Enhances Impact of Glp-1 Based Therapeutic Agents
THOMSON REUTERS · 03-24 12:30
Icovamenib Treatment in Patients With Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function With a 53% Mean Increase in C-Peptide Levels 3 Months After Last Dose
THOMSON REUTERS · 03-24 12:30
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
GlobeNewswire · 03-24 12:30
Biomea Fusion Insiders Recover Some Losses, Which Stand At US$91k
Simply Wall St. · 03-22
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow Jones · 03-19
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 03-03
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones · 03-03
Biomea Fusion CFO Franco Valle Resigns
TIPRANKS · 02-28
Introduction
Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App